Digoxin Medulloblastoma Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2027

Conditions
MedulloblastomaMedulloblastoma, Non-WNT/Non-SHH
Interventions
DRUG

Digoxin

2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.

Trial Locations (14)

10467

RECRUITING

Montefiore Medical Center, The Bronx

20010

NOT_YET_RECRUITING

Children's National Medical Center, Washington D.C.

21218

NOT_YET_RECRUITING

Johns Hopkins University, Baltimore

27514

NOT_YET_RECRUITING

University of North Carolina, Chapel Hill

28204

RECRUITING

Levine Cancer Institute, Charlotte

32207

NOT_YET_RECRUITING

Nemours Jacksonville, Jacksonville

33136

NOT_YET_RECRUITING

University of Miami, Miami

33607

NOT_YET_RECRUITING

St. Joseph's Children's Hospital, Tampa

33701

NOT_YET_RECRUITING

Johns Hopkins All Children's, St. Petersburg

35233

RECRUITING

University of Alabama at Birmingham Children's of Alabama, Birmingham

37232

NOT_YET_RECRUITING

Vanderbilt University Medical Center, Nashville

63130

RECRUITING

Washington University St. Louis, St Louis

75390

NOT_YET_RECRUITING

UT Southwestern, Dallas

06106

NOT_YET_RECRUITING

Connecticut Children's Medical Center, Hartford

All Listed Sponsors
collaborator

National Pediatric Cancer Foundation

OTHER

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER